TLX Q4 2025: Trough Valuation With a Ticking Clock

The Setup

Telix is a radiopharmaceutical company with two businesses: a cash machine (Precision Medicine imaging, $622M revenue, 22% growth) and a free option (therapeutics pipeline, 3 Phase 3 programs, no revenue). Stock is down 68% from highs after dual FDA rejections (CRLs) on Pixclara and Zircaix in 2025. Market cap $2.6B USD. 14/14 analysts say Buy with a mean target implying +143% upside. CEO bought stock at current levels in November — after the bad news.

The earnings call itself was fine. Revenue in line, EBITDA in line, 2026 guidance of $950-970M (20-25% growth) based on approved products only. No blowups. The story is about what comes next.

What the Market Is Pricing

Reverse-engineering from the stock price:

• P(pipeline delivers value) = 27%
• P(bear/distressed outcome) = 70%
• P(therapeutic validation) = 8%

Per-catalyst implied probabilities: Pixclara approval ≈30%, Zircaix ≈25%, ProstACT futility pass ≈12%, PM growth sustains ≈40%.

The market is pricing every single catalyst as more likely to fail than succeed. All of them.

Where the Market May Be Wrong

Pixclara at 30% implied is the weakest link in the bear case. Single-issue CRL. Historical reapproval rate for single-issue CRLs is 80-85%. Orphan drug and fast track designation — FDA wants this approved. Management says issue is addressed. Even discounting for Telix's proven regulatory incompetence (they got TWO CRLs in one year), 75% feels more defensible than 30%.

ProstACT at 12% implied ignores a revealed signal. The independent DSMB reviewed Part 1 safety data and cleared Part 2 randomization. Part 2 is already recruiting ex-US. They don't let you randomize patients if the safety data is bad. CEO on the call: "you will not have long to wait" for Part 1 data disclosure + FDA submission for US enrollment. The data release is imminent — days to weeks, not months.

Market is pricing this at coin-flip-minus-odds. DSMB clearance + active recruitment says the safety data is positive. The question is efficacy (futility analysis Q4 2026), but market isn't even giving credit for the safety milestone that's already passed.

The structural selling thesis. Australian-listed company that crashed 68%. Tax-loss selling through Dec 2025 / Jan 2026. Australian institutional funds forced to mark down and potentially sell. OTC listing in the US means no ETF inclusion, no options market, thin institutional coverage. Forced sellers + no natural buyers = mechanical mispricing that has nothing to do with fundamentals. This is the cleanest form of alpha — price driven by flows, not information.

Cross-ticker confirmation from Cardinal Health. CAH's nuclear/theranostics segment grew revenue 30% YoY in Q2 FY2026. 70+ products in their nuclear pipeline. The distribution infrastructure is expanding. This isn't a Telix-specific story — the entire radiopharmaceutical market is growing fast. Telix's vertical integration ($500M invested in RLS nuclear pharmacy network) positions them to capture more margin as volume grows. Products that decay in hours require last-mile delivery — you can't Amazon Prime a radiopharmaceutical. That's a real moat.

Where I May Be Wrong

The convertible bond put is the risk I almost missed. A$650M in convertible bonds at 2.375%, conversion price A$24.78. Bondholders can put them back at par on July 30, 2027. Stock is A$9.68 — those converts are 61% out of the money. If the stock doesn't recover above the conversion price by mid-2027, bondholders will put, and the company needs A$650M in cash it doesn't have ($142M on hand).

The F-3ASR shelf registration filed on earnings day (Feb 20, 2026) creates the mechanism for an equity raise. At current prices, that would be massively dilutive. The math: A$650M at A$9.68 = 67M new shares against a 339M share base = 20% dilution. And that assumes they raise at current price, not at a discount.

This creates a ticking clock. Catalysts don't just need to land — they need to land fast enough to recover the stock before July 2027. The ProstACT futility analysis in Q4 2026 becomes the pivotal event: if it passes, stock likely recovers, converts stay alive, no dilution. If it fails, death spiral — stock drops, converts get put, dilutive raise, more selling.

Regulatory execution is genuinely uncertain. Two CRLs in one year isn't bad luck — it's a pattern. Management "made extensive changes to the regulatory affairs team" which is corporate-speak for "we fired people." The new team is unproven. Zircaix has "a number of issues" to resolve, not just one. Even with Type A meeting alignment, FDA is unpredictable.

PSMA competitive pressure is a gap I couldn't fill. Management mentioned "ongoing competitive pressure" without naming names. Lantheus (LNTH, $5B market cap, PyL/Pylarify) is the direct US competitor. LNTH trades at 3.3x revenue — roughly the same as Telix on current numbers but with US listing liquidity, proven regulatory execution, and established market position. Lantheus insiders have been selling heavily ($191M Farallon dump in Aug 2025). The PSMA imaging market may be maturing faster than Telix's growth story implies.

PwC adverse ICFR opinion on the FY2025 audit (related to RLS acquisition integration). Common for first-year acquisitions, but it signals integration isn't complete and adds governance noise for institutional investors already skeptical of the company.

The Insider Signal

CEO Behrenbruch sold 2M shares at A$18.39 in Feb 2025 (A$36.8M — near the top). Then bought 100,708 shares at A$9.67 in Nov 2025 — after both CRLs. That's a voluntary open-market purchase, post-bad-news, at the trough. He's the most informed person at the company. He's seen the ProstACT data process, knows the resubmission plans, understands the convertible bond maturity.

The buy is real signal. But context matters: A$974K is 2.6% of what he took off the table. Not exactly backing up the truck. If this were a screaming buy, the CEO with A$36.8M in recent liquidity could have put A$5M or A$10M to work.

Co-founder Kluge holds 22.6M shares (6.7% of the company) through the 68% drawdown — hasn't sold. No insider selling at current lows from anyone. The absence of selling is itself a signal.

Scenario Model (18 months, USD)

EV: $10.88 (+41.5% from $7.69 current)

Annualized raw return ≈27%. Less industry ≈12%. Raw alpha ≈15%. After edge adjustment (45% — edge concentrated in ProstACT DSMB inference and Pixclara CRL base rates): forward alpha ≈7% annualized.

Verdict

This is an interesting asymmetric setup with a structural flaw.

The asymmetry: market prices pipeline at zero, but base rates and revealed signals (DSMB clearance, single-issue CRL, CEO buying) suggest pipeline value is materially positive. Structural selling (tax-loss, AU fund markdowns, OTC illiquidity) may explain the gap between 14/14 analyst Buy and 68% drawdown.

The flaw: the A$650M convertible bond put in July 2027 creates a hard deadline and a potential death spiral if catalysts don't land. This isn't a "wait and see" — the clock is ticking.

The honest position: watchlist with a trigger. If ProstACT Part 1 data is positive and stock doesn't re-rate immediately, that's the entry — the safety data de-risks the survival path to the futility analysis, which de-risks the convert. If the company announces convert refinancing on reasonable terms, that removes the structural flaw entirely.

Buying here blind requires conviction that at least one near-term catalyst lands AND that the convert is manageable. The CEO seems to think so. His A$974K says "yes but small." That's about right.